Arcturus Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Thomas Shrader from BTIG maintained a Buy rating on the stock and has a $23.00 price target.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Thomas Shrader has given his Buy rating due to a combination of factors, including early but compelling clinical data in both the OTC deficiency and cystic fibrosis programs. ARCT-810 has shown that Arcturus’s platform can reliably deliver mRNA to the liver and drive protein production, which not only supports the OTC opportunity but also validates the technology for a broad set of future indications.
At the same time, ARCT-032 has generated encouraging signals in cystic fibrosis, particularly in reducing mucus plugging, and the next 12‑week study is designed to be less noisy and more definitive by extending treatment and tightening patient selection. Combined with a solid cash position and a vaccine platform that, if regulatory and public perception hurdles are cleared, could offer substantial upside, Shrader’s DCF-based valuation supports a positive risk‑reward profile that underpins his Buy recommendation.
According to TipRanks, Shrader is a 4-star analyst with an average return of 7.5% and a 41.84% success rate. Shrader covers the Healthcare sector, focusing on stocks such as Vaxcyte, Opus Genetics, and Bright Minds Biosciences.